Hop Compounds on the Immune System (VH)
Effect of Iso-alpha Acids and Xanthohumol on the Human Immune System
1 other identifier
interventional
14
1 country
1
Brief Summary
The aim of the present study is to determine the effect of Iso-alpha-Acids and Xanthohumol from hops on the immune response of healthy participants over a timeframe of 6 hours.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2022
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 30, 2022
CompletedFirst Submitted
Initial submission to the registry
January 17, 2024
CompletedFirst Posted
Study publicly available on registry
February 29, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2025
CompletedApril 15, 2025
April 1, 2025
3.4 years
January 17, 2024
April 10, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Changes in parameters of immune response
Changes in concentration of interleukin 6 (ng/ml) in cell culture supernatant of stimulated cells.
6 hours
Changes in parameters of immune response
Changes in concentration of interleukin 1 beta (ng/ml) in cell culture supernatant of stimulated cells.
6 hours
Study Arms (3)
Xanthohumol
EXPERIMENTALParticipants receive a study drink supplemented with Xanthohumol (0mg = Placebo; 0,125 mg; 0,375 mg or 0,75 mg soluble Xanthohumol)
Iso-alpha-Acids
EXPERIMENTALParticipants receive a study drink supplemented with Xanthohumol (0 mg = Placebo; 15 mg, 45 mg or 90 mg Iso-alpha-Acids)
Xanthohumol/Iso-alpha-Acids
EXPERIMENTALParticipants receive a study drink supplemented with Xanthohumol + Iso-alpha-Acids (0 mg = Placebo; 0,125 mg + 15 mg, 0,375 mg + 45 mg or 0,75 mg + 90 mg soluble Xanthohumol + Iso-alpha-Acids)
Interventions
Participants receive a study drink supplemented with Xanthohumol (0 mg = Placebo, 0,125 mg, 0,375 mg or 0,75 mg soluble Xanthohumol)
Participants receive a study drink supplemented with Iso-alpha-Acids (0 mg = Placebo, 15 mg, 45 mg or 90 mg Iso-alpha-Acids)
Participants receive a study drink supplemented with Xanthohumol + Iso-alpha-Acids (0 mg = Placebo, 0,125 mg + 15 mg , 0,375 mg + 45 mg or 0,75 mg + 90 mg soluble Xanthohumol + Iso-alpha-Acids)
Eligibility Criteria
You may qualify if:
- healthy
- BMI: \>18,5 kg/m² or \<30 kg/m²
You may not qualify if:
- food intolerances
- food allergies
- chronic inflammatory diseases
- metabolic diseases
- intake of immunosuppressive medication
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Vienna
Vienna, 1090, Austria
MeSH Terms
Interventions
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
January 17, 2024
First Posted
February 29, 2024
Study Start
May 30, 2022
Primary Completion
October 31, 2025
Study Completion
December 30, 2025
Last Updated
April 15, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share